Procter & Gamble Health Ltd
Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 Aug 2026, 02:05 PM IST · BSE ID: 2d6ececd-4b7d-4efe-adee-c76308e76537
View Original BSE Filing (PDF)
💡
In Simple Terms
Procter & Gamble Health saw sales increase by 7% and profit by 45% for the quarter.
🤖 AI Summary
- Sales for Procter & Gamble Health reached ₹356 crores for the quarter ended June 30, 2026, up 7% year-over-year.
- Reported Profit After Tax (PAT) increased by 45% to ₹96 crores for the quarter ended June 30, 2026.
- Operational PAT, excluding one-time asset sale proceeds, stood at ₹72 crores, representing a 9% increase year-over-year.
- Growth attributed to strong brand fundamentals, superior retail execution, and positive consumer response to innovations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Reported Profit After Tax (PAT)
₹96 crores
45%
Operational Profit After Tax (PAT)
₹72 crores
9%
🏢 How This Affects the Company
The company's sales growth indicates continued demand for its VMS products and effectiveness of new innovations and retail execution strategies.
Reported PAT of ₹96 crores includes a boost from one-time asset sale proceeds, while operational PAT of ₹72 crores reflects core business profitability.
Strengthened supply chain and go-to-market capabilities supported the sales growth and improved operational profitability during the quarter.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected as this filing provides an update on the company's financial performance for the first quarter of Financial Year 2026-2027.
🔍
Management Signal
Management is focused on driving balanced growth and value creation through a focused portfolio, superiority, and operational efficiency.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — observe if sales growth above 7% is sustained.
Update on new innovations — assess impact on consumer response and market share.
Management commentary on future supply chain and go-to-market initiatives.
LOW RISK
Filing reports positive financial results with no new risks identified.
💡 Investor Takeaway
Procter & Gamble Health reported sales of ₹356 crores, up 7% year-over-year, and reported PAT of ₹96 crores, up 45% for the quarter ended June 30, 2026. Operational PAT rose 9% to ₹72 crores, excluding one-time asset sale proceeds.
⚖️ Strengths & Concerns
✅ Positives
- Sales increased by 7% to ₹356 crores for the quarter ended June 30, 2026, driven by strong brand fundamentals.
- Reported Profit After Tax (PAT) grew by 45% to ₹96 crores, supported by sales growth and one-time asset sale proceeds.
⚠️ Concerns
- A portion of the reported PAT growth for the quarter ended June 30, 2026, was due to one-time proceeds from an asset sale.
- Operational PAT growth of 9% to ₹72 crores was lower than the reported PAT growth, indicating reliance on non-core income for overall PAT.
❓ Frequently Asked Questions
What were Procter & Gamble Health's sales for the quarter ended June 30, 2026?
Procter & Gamble Health reported sales of ₹356 crores for the quarter ended June 30, 2026, an increase of 7% from a year ago.
What was Procter & Gamble Health's reported Profit After Tax (PAT) for Q1 FY27?
The reported Profit After Tax (PAT) for Procter & Gamble Health for the quarter ended June 30, 2026, was ₹96 crores, up 45% year-over-year.
How much was Procter & Gamble Health's operational PAT for the quarter ended June 30, 2026?
Procter & Gamble Health's operational Profit After Tax (PAT) for the quarter ended June 30, 2026, was ₹72 crores, which is a 9% increase year-over-year, excluding one-time proceeds from an asset sale.
What contributed to Procter & Gamble Health's sales growth in Q1 FY27?
Sales growth was driven by strong brand fundamentals, superior retail execution, and positive consumer response to new innovations for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.